Press Releases

Investor Menu

Overview
News & Events
- Press Releases
- Events
Financials & Filings
- SEC Filings
- Annual Reports
Governance
Stock Info
- Stock Quote & Chart
- Analyst Coverage
IR Resources

Year

Mar 02, 2023

Biomea Fusion To Participate In Upcoming Investor Events

REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that

Jan 17, 2023

Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors

BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) A pan-KRAS inhibitor targeting multiple KRAS mutations (including G12C, G12D and G12R, among others)

Jan 09, 2023

Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones

REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic

Jan 04, 2023

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219

COVALENT-111, now underway in the US, has completed Phase I and is currently enrolling type 2 diabetes patients in the Phase II randomized, placebo-controlled portion of the trial BMF-219, an orally available covalent menin inhibitor, is being evaluated for its potential to enable the

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 14 of 14

admin-home
info
address-book
medkit
flask
briefcase
pressthis
map-signs

linkedin
twitter
facebook
instagram
mail

Scroll to top